Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
Patent 8057789 Issued on November 15, 2011. Estimated Expiration Date: October 31, 2027. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The present invention provides compositions and methods of using placental stem cells that originate from a postpartum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
Other References
Notice of Allowance dated Apr. 21, 2011 in U.S. Appl. No. 12/341,961.
Non Final Office Action dated Apr. 18, 2011 in U.S. Appl. No. 12/030,170.
Non-Final Office Action dated Apr. 21, 2011 in U.S. Appl. No. 11/648,804.
Advisory Action dated Oct. 7, 2009 in U.S. Appl. No. 10/721,144.
Office Action dated Mar. 18, 2010 in U.S. Appl. No. 10/721,144.
Final Office Action dated Sep. 14, 2010 in U.S. Appl. No. 10/721,144.
Non Final Office Action dated Feb. 1, 2011 in U.S. Appl. No. 10/721,144.
Zhao et al., “Transplanted Human Bone Marrow-Derived Adult Stem Cells Survive and Improve Functional Outcome in a Rat Model of Cortical Ischemic Brain Injury,” Experimental Neurology, Academic Press, New York, 164(2):465-466, XP001159669 (2000).
Yin et al., “AC133, a novel maker for human hematopoietic stem and progenitor cells” Blood 90(12):5002-5012 (1997).
Xu et al., “Feeder-free growth of undifferentiated human embryonic stem cells” Nature Biotechnology 19:971-974 (2001).
Reubinoff, “Neural Progenitors from Human Embryonic Stem Cells,” Nature Biotech. 19(12):1134-1140 (2001).
Ponticiello et al. “Gelatin-based resorbable sponge as a carrier matrix for human mesenchymal stem cells in cartilage regeneration therapy” Journal of Biomedical Materials Research 52:246-255 (2000).
Marmont, “New Horizons in the Treatment of Autoimmune Diseases: Immunoablation and Stem Cell Transplantation,” Ann. Rev. Medicine 51:115-134 (2000).
Malek et al., “Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system,” European Journal of Physiology 427:157-161 (1994).
Jaroscak et al., “Preliminary characterization of the surface staining of placental derived adherent cells: a potential new source of stroma for umbilical cord blood (UCB) expansion,” Blood 96(11, Pt 2) (2000).
Nagayama et al., “Immunological reconstitution after cord blood transplantation for an adult patient”. Bone Marrow Transplantation 24: 211-13 (1999).
Hsieh et al. “Effects of glucose on placental hormones in the human term placenta in vitro” J. Formos. Med. Assoc. 96:309-313 (1997).
Heidaran, Disclosure Document No. 457045 for “A Method or Process for the Treatment of Degenerative Conditions or Cancer Employing Custom Fabricated Organ Tissue Grafts Using Cells Isolated, Expanded, and Stored at Birth”, 15 pages, stamped received by OIPE on May 28, 1999, paper dated May 13, 1999.
Fassas at al., “Autologous Stem Cell Transplantation in Progressive Multiple Sclerosis—An Interim Analysis of Efficacy,” J. Clin. irniThinol., 20(1):24-30 (2000).
Extended European Search Report for EP Application No. 10185142.6-2401.
Extended European Search Report for EP Application No. 10184356.3-2401.
Extended European Search Report dated Mar. 30, 2011 for EP Application No. 10182303.7-2401.
Extended European Search Report dated Mar. 3, 2011 for EP Application No. 10183378.8-2401.
Extended European Search Report dated Mar. 28, 2011 for EP Application No. 10182433.2-2401.
Extended European Search Report dated Mar. 25, 2011 for EP Application No. 10183301.0-2401.
Extended European Search Report dated Mar. 25, 2011 for EP Application No. 10182485.2-2401.
Extended European Search Report dated Mar. 25, 2011 for EP Application No. 10182362.3-2401.
Extended European Search Report dated Mar. 25, 2011 for EP Application No. 10182243.5-2401.
Extended European Search Report dated Mar. 25, 2011 for EP Application No. 10182195.7-2401.
Extended European Search Report dated Mar. 22, 2011 for EP Application No. 10183252.5-2401.
Extended European Search Report dated Mar. 11, 2011 for EP Application No. 10183435.6-2401.
Denison et al., “Cytokine secretion by human fetal membranes, decidua and placenta at term” Human Reproduction 13(12):3560-3565 (1998).
Conget et al. “Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells” Journal of Cellular Physiology 181:67-73 (1999).
Abe, “Therapeutic Potential of Neurotrophic Factors and Neural Stem Cells Against Ischemic Brain Injury, ” Journal of Cerebral Blood Flow and Metabolism, Raven Press, Ltd., New York, 20(10): 1393-1408 (2000).
U.S. Appl. No. 13/182,250, filed Jul. 13, 2011, Hariri et al.
U.S. Appl. No. 13/108,901, filed May 16, 2011, Hariri.
U.S. Appl. No. 12/108,891, filed May 16, 2011, Hariri.
U.S. Appl. No. 13/108,871, filed May 16, 2011, Hariri.
U.S. Appl. No. 13/107,778, filed May 13, 2011, Edinger et al.
U.S. Appl. No. 12/107,727, filed May 13, 2011, Edinger et al.
U.S. Appl. No. 13/089,029, filed Apr. 18, 2011, Hariri et al.
U.S. Appl. No. 13/081,422, filed Apr. 6, 2011, Edinger.
U.S. Appl. No. 13/081,415, filed Apr. 6, 2011, Abbot.
U.S. Appl. No. 13/,071,437, filed Mar. 24, 2011, Zhang et al.
02;International Business Machines Corporation
Notice of Allowance dated Feb. 18, 2011 in U.S. Appl. No. 12/341,961.
Non Final Office Action dated Sep. 1, 2010 in U.S. Appl. No. 12/341,961.
Non Final Office Action dated Jul. 9, 2010 in U.S. Appl. No. 12/259,259.
Non Final Office Action dated Dec. 15, 2009 in U.S. Appl. No. 12/030,170.
Non Final Office Action dated Jun. 4, 2010 in U.S. Appl. No. 12/030,170.
Final Office Action dated Nov. 3, 2010 in U.S. Appl. No. 12/030,170.
Non Final Office Action dated May 24, 2010 in U.S. Appl. No. 11/982,211.
Final Office Action dated Nov. 3, 2010 in U.S. Appl. No. 11/982,211.
Non Final Office Action dated Jun. 7, 2010 in U.S. Appl. No. 11/980,012.
Notice of Allowance dated Nov. 29, 2010 in U.S. Appl. No. 11/980,012.
Non Final Office Action dated Jul. 15, 2010 in U.S. Appl. No. 11/982,291.
Final Office Action dated Feb. 1, 2011 in U.S. Appl. No. 11/982,291.
Non-Final Office Action dated Oct. 21, 2009 in U.S. Appl. No. 11/648,804.
Final Office Action dated May 20, 2010 in U.S. Appl. No. 11/648,804.
Office Action dated Jan. 26, 2009 in U.S. Appl. No. 11/648,813.
Final Office Action dated Oct. 27, 2009 in U.S. Appl. No. 11/648,813.
Non Final Office Action dated Jun. 7, 2010 in U.S. Appl. No. 11/648,813.
Notice of Allowance dated Jan. 10, 2011 in U.S. Appl. No. 11/648,813.
Non Final Office Action dated Feb. 4, 2009 in U.S. Appl. No. 11/592,544.
Final Office Action dated Aug. 4, 2010 in U.S. Appl. No. 11/592,544.
Office Action dated Oct. 4, 2005 in U.S. Appl. No. 10/721,144.
Final Office Action dated Jan. 11, 2006 in U.S. Appl. No. 10/721,144.
Advisory Action dated Feb. 6, 2006 in U.S. Appl. No. 10/721,144.
Office Action dated Jun. 14, 2006 in U.S. Appl. No. 10/721,144.
Office Action dated Dec. 28, 2006 in U.S. Appl. No. 10/721,144.
Final Office Action dated Jun. 27, 2007 in U.S. Appl. No. 10/721,144.
Office Action dated Feb. 5, 2008 in U.S. Appl. No. 10/721,144.
Office Action dated Apr. 2, 2009 in U.S. Appl. No. 10/721,144.
Advisory Action dated Aug. 17, 2009 in U.S. Appl. No. 10/721,144.
Office Action dated Apr. 20, 2007 in U.S. Appl. No. 11/187,400.
Office Action dated May 22, 2008 in U.S. Appl. No. 11/187,400.
Office Action dated Jan. 4, 2008 in U.S. Appl. No. 11/187,400.
Advisory Action dated Sep. 8, 2008 in U.S. Appl. No. 11/187,400.
Office Action dated Feb. 20, 2009 in U.S. Appl. No. 11/187,400.
Office Action dated Jun. 12, 2006 in U.S. Appl. No. 10/874,828, now US Patent No. 7,468,276.
Office Action dated Dec. 13, 2007 in U.S. Appl. No. 10/874,828, now US Patent No. 7,468,276.
Office Action dated Apr. 6, 2007 in U.S. Appl. No. 10/874,828, now US Patent No. 7,468,276.
Advisory Action dated Feb. 20, 2007 in U.S. Appl. No. 10/640,428, now US Patent No. 7,255,879.
Office Action dated Jan. 19, 2006 in U.S. Appl. No. 10/640,428, now US Patent No. 7,255,879.
Office Action dated Oct. 18, 2006 in U.S. Appl. No. 10/640,428, now US Patent No. 7,255,879.
Notice of Allowance May 21, 2007 in U.S. Appl. No. 10/640,428, now US Patent No. 7,255,879.
Office Action dated Aug. 29, 2006 in U.S. Appl. No. 10/449,248.
Office Action dated Apr. 26, 2007 in U.S. Appl. No. 10/449,248.
Office Action dated Nov. 20, 2006 in U.S. Appl. No. 10/411,655, now US Patent No. 7,498,171.
Office Action dated May 18, 2006 in U.S. Appl. No. 10/411,655, now US Patent No. 7,498,171.
Office Action dated Jul. 11, 2007 in US Patent Application No. 10/411,655, now US Patent No. 7,498,171.
Office Action dated Feb. 28, 2008 in U.S. Appl. No. 10/411,655, now US Patent No. 7,498,171.
Notice of Allowance dated Oct. 30, 2008 in U.S. Appl. No. 10/411,655, now US Patent No. 7,498,171.
Office Action dated Oct. 10, 2006 in U.S. Appl. No. 10/366,671, now US Patent No. 7,311,905.
Office Action dated May 14, 2007 in U.S. Appl. No. 10/366,671, now US Patent No. 7,311,905.
Office Action dated Jan. 19, 2006 in U.S. Appl. No. 10/366,671, now US Patent No. 7,311,905.
Notice of Allowance dated Sep. 10, 2007 in U.S. Appl. No. 10/366,671, now US Patent No. 7,311,905.
Office Action dated Sep. 23, 2004 in U.S. Appl. No. 10/074,976, now US Patent No. 7,311,904.
Office Action dated Sep. 20, 2006 in U.S. Appl. No. 10/074,976, now US Patent No. 7,311,904.
Office Action dated Mar. 22, 2007 in U.S. Appl. No. 10/074,976, now US Patent No. 7,311,904.
Office Action dated Jan. 5, 2006 in U.S. Appl. No. 10/074,976, now US Patent No. 7,311,904.
Notice of Allowance dated Aug. 16, 2007 in U.S. Appl. No. 10/074,976, now US Patent No. 7,311,904.
Office Action dated May 7, 2003 in U.S. Appl. No. 10/004,942, now US Patent No. 7,045,148.
Office Action dated Jun. 20, 2005 in U.S. Appl. No. 10/004,942, now US Patent No. 7,045,148.
Office Action dated Jun. 15, 2004 in U.S. Appl. No. 10/004,942, now US Patent No. 7,045,148.
Office Action dated Dec. 5, 2003 in U.S. Appl. No. 10/004,942, now US Patent No. 7,045,148.
Office Action dated Dec. 16, 2004 in U.S. Appl. No. 10/004,942, now US Patent No. 7,045,148.
Notice of Allowance dated Sep. 15, 2005 in U.S. Appl. No. 10/004,942, now US Patent No. 7,045,148.
Office Action dated Oct. 20, 2004 in U.S. Appl. No. 10/076,180.
Office Action dated Mar. 18, 2004 in U.S. Appl. No. 10/076,180.
Office Action dated Jun. 20, 2005 in U.S. Appl. No. 10/076,180.
Office Action dated Aug. 28, 2003 in U.S. Appl. No. 10/076,180.
Advisory Action dated Jul. 12, 2004 in U.S. Appl. No. 10/076,180.
Zhang, et al., “Human Placenta-Derived Mesenchymal Progenitor Cells Support Culture Expansion of Long-Term Culture-Initiating Cells from Cord Blood CD34+ Cells.” Exp. Hematol. 32: 657-664 (2004).
Yen, et al, “Isolation of multipotent cells from human term placenta” Stem Cells (Dayton, Ohio) 2005, vol. 23, No. 1, pp. 3-9, XP002443187 ISSN: 1065-5099 (Jan. 2005).
Xu, et al., “High Sensitivity of Megakaryocytic Progenitor Cells Contained in Placental/Umbilical Cord Blood to the Stresses During Cryopreservation,” Bone Marrow Transplantation 34: 537-543 (2004).
Wiesmann, et al., “Effects of Caspase Inhibitors on Hematopoietic Engraftment After Short-Term Culture,” Cell. Transplant. 11(4):351-358 (2002).
Roth, et al., “Human Placental Cytotrophoblats Produce the Immunosuppressive Cytokine Interliukin 10,” J. Exp. Med. 184(2):539-548 (1996).
Reyes, et al., “Purification and ex vivo Expansion of Postnatal Human Marrow Mesodermanl Progenitor Cells,” Blood 98(9):2615-2625 (2001).
Pittenger., et al. “Multilineage Potential of Adult Human Mesenchymal Stem Cells.” Science 284(5411):143-147 (1999).
Pera, et al., “Human Embryonic Stem Cells,” J. Cell. Sci. 113:5-10 (2000).
Paludan, et al., “Immune Suppression by Placenta Derived Adherent Cells (PDAC) Correlate with Monocyte Chemoattractant Protein-1 and 1L-2 Secretion,” Blood 108(11) Part II, p. 48B (2006) (abstract only).
Miki, et al., “Stem Cell Characteristics of Amniotic Epithelial Cells.” Stem Cells Express, published online Aug. 9, 2005; doi:10. 1634/stemcells.2004-0357 (2005).
Miki, et al., “Production of Hepatocytes from Human Amniotic Stem Cells.” Hepatology, Abstract 20, vol. 36, No. 4, Pt. 2, (2002).
Miki, et al., “Isolation of Multipotent Stem Cells from Placenta.” AASLD Abstracts, Hepatology, Abstract 279, p. 290A (Oct. 2003).
Mcmaster et al, “Human Placental HLA-G Expression is Restricted to Differentiated Cytotrophoblasts,” J. Immunol. 154(8):3771-3778 (1995).
Lin, et al. “Murine CD200(+)CK7(+) trophoblasts in a poly (I:C)-induced embryo resorption model.” Reproduction (Cambridge), vol. 130, No. 4, pp. 529-537, XP002443406 ISSN: 1470-1626 (Oct. 2005).
Li, et al., “Mesenchymal Stem Cells Derived from Human Placenta Suppress Allogenic Umbilical Cord Blood Lymphocyte Proliferation.” Cell Res. 15: 539-547 (2005).
Lebkowski, et al., “Serum and Plasma Levels of FGF-2 and VEGF in Healthy Blood Donors,” Cancer J. 7(Suppl 2):S83-S93 (2001).
Kawata, et al., “Transcriptional Control of HLA-A,B,C Antigen in Human Placental Cytotrophoblast Isolated Using Trophoblast- and HLA-Specific Monoclonal Antibodies and the Fluorescence-Activated Cell Sorter,” J. Exp. Med. 160(3):633-51 (1984).
Igura, et al., “Isolation and Characterization of Mesencymal Progenitor Cells from Chorionic Villi of Human Placenta,” Cytotherapy 6(6): 543-553 (2004).
Huss, “Isolation of Primary and Immortalized CD34- Hematopoietic and Mesenchymal Stem Cells from Various Sources,” Stem Cells 18:1-9 (2000).
Harbacheuski, et al., “Placenta Derived Adherent Cells (PDACs) Supress Tumor Cells of Diverse Origin.” Blood 108(11):288 (2006).
Frank H G, et al., “Cell culture models of human trophoblast: primary culture of trophoblast—a workshop report.” Placent Apr. 2001, vol. 22 Suppl A, pp. S107-5109, XP002443188 ISSN: 0143-4004 (Apr. 2001).
Fasouliotis, et al., “Human umbilical cord blood banking and transplantation: a state of the art,” Eur. J. Obstet. Gynecol. Reprod. Biol. 90(1):13-25 (2000).
Erices, et al., “Mesenchymal Progenitor Cells in Human Umbilical Cord Blood,” Br. J. Haemotol. 109(1):235-242 Abstract (2000).
Drake, et al., “Human Placental Cytotrophoblasts Attract Monocytes and CD56 (Bright) Natural Killer Cells Via the Actions of Monocyte Inflammatory Protein 1Alpha,” J. Exp. Med. 193(10):1199-1212 (2001).
De Coppi, et al., “Pluripotent Stem Cells Derived from Human Chorionic Villi and Amniotic Fluid for Tissue Engineering Applications.” Experimental Biology/IUPS 2005: Meeting Abstracts, A1366 Abstract 781.7.
De Coppi, et al., “Human Embryonic and Fetal Stem-Cell Isolation from Amniotic Fluid and Placenta for Tissue Reconstruction.” Urology and Reproductive Surgery, vol. 195, No. 3S, Sep. 2002, p. S93.
De Coppi, , et al., “Amniotic Fluid and Chorionic Villi Derived Human Stem Cells for the Engineering of Tissues in Vivo.” The Journal of Urology, vol. 171, No. 4, Supplement, Saturday, May 8, 2004, p. 21, Abstract 81.
Davila, et al., “Use and Application of Stem Cells in Toxicology,” Toxicological Sciences 79:214-223 (2004).
Cosma, et al., “Use and Application of Stem Cells in Toxicology,” SOT 2003 Annual Meeting, p. 4, Abstract 19.
Clark, et al., “Placental Trophoblast from Successful Human Pregnancies Expresses the Tolerance Signaling Molecule, CD200 (OX-2)” Am. J. Reprod. Immunol., 50(3):187-195 (2003).
Chao, et al., “Stem Cell Transplantation (Cord Blood Transplants).” American Society of Hematology p. 354-371 (2004).
Campagnoli, et al., “Identification of Mesenchymal Stem/Progenitor Cells in Human First-Trimester Fetal Blood, Liver, and Bone Marrow.” Blood 98(8):2396-402 (2001).
Sikkema-Raddatz, “Four Years' Cytogenetic Experience with the Culture of Chorionic Villi,” Prenatal Diagnosis 20:950-955 (2000).
Schwab, “Fast and Reliable Culture Method for Cells from 8-10 Week Trophoblast Tissue,” Lancet 323:1082 (1984).
Sapin, “Esterification of Vitamin A by the Human Placenta Involves Villous Mesenchymal Fibrlboasts,” pediatric Research 48(4):565-572 (2000).
U.S. Appl. No. 12/848,007, filed Jul. 30, 2010, Edinger et al.
U.S. Appl. No. 12/846,765, filed Jul. 29, 2010, Edinger et al.
U.S. Appl. No. 12/829,326, filed Jul. 1, 2010, Abbot.
U.S. Appl. No. 12/823,063, filed Jun. 24, 2010, Hariri.
U.S. Appl. No. 12/187,337, filed Aug. 6, 2008, Heidaran et al.
U.S. Appl. No. 09/659,904, filed Sep. 12, 2000, Hariri.
Rameshwar, P. et al., 1999, “Endogenous Hematopoietic Reconstruction Induced by Human Umbilical Cord Blood Cells in Immunocompromised Mice: Implications for Adoptive Therapy,” Exp. Hematol. 27(1):176-85.
Ende, N. et al., 1995, “The Effect of Human Cord Blood on SJL/J Mice After Chemoablation and Irradiation and Its Possible Clinical Significance,” Immunol. Invest. 24(6):999-1012.
Ende, N. et al., 1999, “The Feasibility of Using Blood Bank-Stored (4 Degrees C) Cord Blood, Unmatched for HLA for Marrow Transplantation,” Am. J. Clin. Pathol. 111(6):773-81.
Ende, N., et al., 2000, “Human Umbilical Cord Blood Effect on SOD Mice (Amyotrophic Lateral Sclerosis)” Life Sci. 67(1):53-9.
Ende, N. et al., 2001, “Pooled Umbilical Cord Blood as a Possible Universal Donor for Marrow Reconstruction and Use in Nuclear Accidents,” Life Sci. 69(13):1531-9.
Ende, N. et al., 2001, “Human Umbilical Cord Blood Cells Ameliorate Huntington's Disease in Transgenic Mice,” J. Med., 32(3-4):231-40.
Ende, N. et al., 2001, “Human Umbilical Cord Blood Cells Ameliorate Alzheimer's Disease in Transgenic Mice,” J. Med., 32(3-4):241-7.
Czarneski, J. et al., 1999, “Effects of Cord Blood Transfer on the Hematopoietic Recovery Following Sublethal Irradiation in MRL 1pr/1pr Mice,” Proc. Soc. Exp. Biol. Med. 220(2):79-87.
Chen, R. et al., 2000, “The Potential for the Use of Mononuclear Cells from Human Umbilical Cord Blood in the Treatment of Amyotrophic Lateral Sclerosis is SOD1 Mice,” J. Med. 31(1-2):21-30.
Wang et al. “Enhanced Recovery of Hematopoietic Progenitor and Stem Cells from Cultivated, Postpartum Human Placenta,” Blood 68:183c, Abstract 769 (2001).
Viacord, 2001, Umbilical cord blood can save lives (Informational brochure), Boston: ViaCell CENTR-BRO R1 Oct. 2001.
Thomson et al., 1998, Embryonic stem cell lines derived from human blastocysts. Science. 282 (5391): 1145-7.
Slager 1993, Transforming growth factor-beta in the early mouse embryo: implications for the regulation of muscle formation and implantation. Dev Genet. 14(3):212-24.
Shamblott, et al., 1998, Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A. 95(23):13726-31.
Reyes et al. 2002, Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 109(3):337-46.
Korbling et al., 2002, Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 346(10):738-46.
Hirashima et al. 1999, Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood. 93(4):1253-63.
Himori, et al . 1984, Chemotherapeutic susceptibility of human bone marrow progenitor cells and human myelogenous leukemia cells (HL-60) in co-culture: preliminary report. Int J Cell Cloning. 2(4):254-62.
Hatzopoulos et al. 1998, Isolation and characterization of endothelial progenitor cells from mouse embryos. Development. 125(8):1457-68.
Dushnik-Levinson et al. 1995, Embryogenesis in vitro: study of differentiation of embryonic stem cells. Biol Neonate. 67(2):77-83.
Abkowitz, 2002, Can human hematopoietic stem cells become skin, gut, or liver cells? N Engl J Med. 346(10):770-2.
Ye et al., 2001, “Recovery of placental-derived adherent cells with mesenchymal stem cell characteristics,” Blood 98(11/1):147b Abstract No. 4260.
Yan et al., 2001, Retinoic acid promotes differentiation of trophoblast stem cells to a giant cell fate. Dev Biol. 235(2):422-32.
Wigler et al. 1997, Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell. 11(1):223-32.
Van Bekkum, “The Pluripotent Hemopoietic Stem Cell: Its Identification and Applications,” Verh. Dtsch. Ges. Pathol. 74:19-24 (1990).
Uchimura et al. 1998, Human N-acetylglucosamine-6-O-sulfotransferase involved in the biosynthesis of 6-sulfo sialyl Lewis X: molecular cloning, chromosomal mapping, and expression in various organs and tumor cells. J Biochem (Tokyo). 124(3):670-8.
Turner et al., 1992, “A modified harvest technique for cord blood hematopoietic stem cells,” Bone Marrow Transplantation 10:89-91.
Tremblay et al., 2001, Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes Dev. 15(7):833-8.
Totipotent stem cells, Stem Cells Information Center On-line, 2004.
Thomas and Capecchi, 1987, Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 51(3):503-12.
Szybalska and Szybalska, 1962, Genetics of human cell lines IV: DNA-mediated heritable transformation of a biochemical trait. PNAS 48: 2026-2034.
Srour, 1999, Ex vivo expansion of hematopoietic stem and progenitor cells. Are we there yet? The Journal of Hematotherapy 8:93-102.
Smithies et al. 1985, Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature. 317(6034):230-4.
Santerre et al., 1984, Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene. 30(1-3):147-56.
Sakabe et al., “Functional Differences Between Subpopulations of Mobilized Peripheral Blood-Derived CD34+ Cells Expressing Different Levels of HLA-DR, CD33, CD38 and c-kit Antigens,” Stem Cells 15(11):73-81 (1997).
Ray et al., 1997, CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family.J Biol Chem. Jul. 25, 1997;272(30):18702-8.
Placenta, Encyclopedias Britanica, 2003.
Papaioannou et al., Stem Cell Handbook 2004, 19-31.
Ordi et al., 1998, Am J Surg Pathol 8:1006-1011.
O'Hare et al. 1981, Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. Proc Natl Acad Sci U S A. 78(3):1527-31.
Nadkarni et al. 1984, Effect of retinoic acid on bone-marrow committed stem cells (CFU-c) from chronic myeloid leukemia patients. Tumori. 70(6):503-5.
Myllynen, In Search of Models for Hepatic and Placental Pharmacokinetics, dissertation, University of Oulu (2003).
Mulligan and Berg, 1981 Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase Proc Natl Acad Sci U S A. 78(4):2072-6.
Muhlemann et al., 1995, Placenta 16:367-373.
Moore et al., 1997, “A simple perfusion technique for isolation of maternal intervillous blood mononuclear cells from human placentae,” J. Immunol. Methods 209(1):93-104.
Minguel et al., 2001, Exp Biol Med 226:507-520.
Melchner, et al., 1985, Human placental conditioned medium reverses apparent commitment to differentiation of human promyelocytic leukemia cells (HL60). Blood. 66(6):1469-72.
Ma et al., 1999, Tissue Engineering 5:91-102.
Lowy et al. 1980, Isolation of transforming DNA: cloning the hamster aprt gene. Cell. 22(3):817-23.
Larsson et al., 2002, Angiogenesis 5,107-110.
Kurtzberg et al., 1996, New Eng J Med 335:157-166.
Kozbor et al., 1983, The productrion of monoclonal antibodies from human lymphocytes. Immunology Today 4, 72-79.
Korbling et al., “Peripheral Blood Stem Cell Versus Bone Marrow Allotransplantation: Does the Source of Hematopoietic Stem Cells Matter?” Blood 98(10):2900-2908 (2001).
Kondo et al., “Reduced Interferon Gamma Production by Antigen-Stimulated Cord Blood Mononuclear Cells is a Risk Factor of Allergic Disorders - 6-Year Follow-up Study,” Clin Exp Allergy 28(11):1340-1344 (1998).
Keown et al., 1990, Methods for introducing DNA into mammalian cells. Methods Enzymol. 185:527-37.
Hows “Status of Umbilical Cord Blood Transplantation in the Year 2001,” J Clin Pathol 54(6):428-434 (2001).
Gluckman et al., “Results of Unrelated Umbilical Cord Blood Hematipoietic Stem Cell Transplant,” Transfusion Clinique el Biologique 8(3):146-154 (2001).
Gluckman et al., “Cord Blood Hematopoietic Stem Cells: Bilogy and Transplantation,” In: Hematology. American Society of Hematology Education program Book, 1998. p. 1-14.
Genbacev et al. 1995,Maternal smoking inhibits early human cytotrophoblast differentiation. Reprod Toxicol. 9(3):245-55.
Ende, N., “Berashis Cells in Human Umbilical Cord Blood Vs. Embryonic Stem Cells,” Journal of Medicine 33(1-4):167-171 (2002).
Ende, N. & Chen R., “Parkinson's Disease Mice and Human Umbilical Cord Blood,”Journal of Medicine 33(1-4):173-180 (2002).
Ende N. “Collection of Umbilical Cord Blood for Transplantation,” Blood 80(6):1623-1624 (1992).
Ende, M. et al., “Hemapoetic Transplantation By Means of Fetal (Cord) Blood: A New Method,” Va Med Mon 99:276-280 (1972).
Emerson, 1996, Ex vivo expansion of hematopoietic precursors, progenitors and stem cells. The next generation of cellular therapeutics, Blood 87(8):3082-3088.
Elchalal et al., 2000, “Postpartum unbilical cord blood collection for transplantation: a comparison of three methods,” Am. J. of Obstetrics & Gyn. 182(1 Pt 1):227-232.
Douay et al, 1995. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. Bone Marrow Transplant. 15(5):769-75.
Dorrel, 2000, Expansion of human cord blood CD34+CD38− cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulation cell (SRC) frequency: dissociation of SRC phenotype and function, Blood, 95(1)102-110.
DeLoia et al, 1998, Effects of methotrexate on trophoblast proliferation and local immune responses. Hum Reprod. 13(4):1063-9.
Damjanov et al., 1993, Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest. 68(2):220-32.
Cote et al., 1983, Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A. 80(7):2026-30.
Cord Blood Stem Cell, Mesh Term Database 2003.
Contractor et al., 1984, “A comparison of the effects of different perfusion regimens on the structure of the isolated human placental lobule,” Cell Tissue Res. 237:609-617.
Cole et al., 1985, EBV-Hydradoma techigue and its application to human lung cancer. In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 77-96.
CD34, Medline Mesh Database, 2004.
Cardoso et al., “Release From Quiescence of CD34+ CD38- Human Umbilical Cord Blood Cells Reveals Their Potentiality to Engraft Adults,” Proc Natl Acad Sci USA 90(18):8707-8711 (1993).
Caplan, “The Mesengenic Process,” Clin. Plast. Surg. 21(3):429-435 (1994).
Belvedere et al., 2000, “Increased blood volume and CD34(+)CD38(−) progenitor cell recovery using a novel umbilical cord blood collection system,” Stem Cells 18(4):245-251.
Barry, 1994, “Where do all the placentas go?” Canadian Journal of Infection Control 9(I):8-10.
Ashihara et al., “Successful Peripheral Blood Stem Cell,Transplantation for Myelodysplastic Syndrome,” Bone Marrow Transplantation 24(12:1343-1345 (1999).
Addison et al., “Metabolism of Prednisolone by the Isolated Perfused Human Placental Lobule”, J. Ster. Biochem Mol. Biol., vol. 39 No. 1, pp. 83-90 (1991).
Chen et al., “Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats,”Stroke 32(11):2682-2688 (2001).
Viacord, “Unbilical Cord Blood Can Save Lives.” Informational Brochure, Boston: ViaCell CENTR-BR RI (Oct. 2001).
Thomson, et al., “Embryonic Stem Cell Lines Derived from Human Blastocysts.” Science 282(5391):1145-47 (1998).
Slager, “Transforming Growth Factor-Beta in the Early Mouse Embryo: Implications for the Regulation of Muscle Formation and Implantation.” Dev. Genet. 14(3):212-24 (1993).
Shamblott, et al., “Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells.” Proc. Nat'l. Acd. Sci. U S A. 95(23):13726-31 (1998).
Sakuragawa et al., “Human amniotic epithelial cells are promising transgene carriers for allogeneic cell transplantation into liver,” .J. Hum. Genet. 45:171-176 (2000).
Sakuragawa et al., “Expression of markers for both neuronal and glial cells in human amniotic epithelial cells,” Neuroscience Letters 209:9-12 (1996).
Reyes, et al., “Origin of Endothelial Progenitors in Human Postnatal Bone Marrow.” J. Clin. Invest. 109(3):337-46.
Korbling, et al., “Hepatocytes and Epithelial Cells of Donor Origin in Recipients of Peripheral-Blood Stem Cells.” N. Engl. J. Med. 346(10):738-46 (2002).
Hirashima, et al., “Maturation of Embryonic Stem Cells into Endothelial Cells in an in Vitro model of Vasculogenesis.” Blood. 93(4):I253-63 (1999).
Himori, et al. Chemotherapeutic Susceptibility of Human Bone Marrow Progenitor Cells and Human Myelogenous Leukemia Cells (HL-60) in Co-Culture: Preliminary Report. Int. J. Cell Cloning. 2(4):254-62 (1984).
Hatzopoulos, et al., “Isolation and Characterization of Endothelial Progenitor Cells from Mouse Embryos.” Development. 125(8): 1457-68 (1998).
Dushnik-Levinson, et al., “Embryogenesis in Vitro: Study of Differentiation of Embryonic Stem Cells.” Biol. Neonate. 67(2):77-83.
De Coppi et al., “Human fetal stem cell isolation from amniotic fluid for tissue reconstruction,” J. Urology 167(4 Supp.) 85 (Abstract 338) (2002).
Chin et al., “Enhanced Interferon Production and Lymphokine-Activated Cytotoxicity of Human Placental Cells,” Cellular Immunology 113:1-9 (1988).
Abkowitz, “Can Human Hematopoietic Stem Cells Become Skin, Gut, or Liver Cells?” N. Engl. J. Med. 346(10):770-2 (2002).
U.S. Appl. No. 11/648,824, filed Dec. 28, 2006, Heidaran.
U.S. Appl. No. 11/648,813, filed Dec. 28, 2006, Edinger.
U.S. Appl. No. 11/648,812, filed Dec. 28, 2006, Heidaran.
U.S. Appl. No. 11/648,804, filed Dec. 28, 2006, Edinger.
U.S. Appl. No. 11/648,802, filed Dec. 28, 2006, Heidaran.
U.S. Appl. No. 11/580,625, filed Oct. 13, 2006, Heidaran.
U.S. Appl. No. 11/580,588, filed Oct. 13, 2006, Paludan.
October 31, 2027. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
